MedTrace Logo

Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic Alcoholics

NCT00226109 · Status: SUSPENDED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-10-20

No results posted yet for this study

Summary

Chronic alcoholics suffer from weak skeletal and cardiac muscle. The investigators have discovered a beneficial effect of spironolactone-treatment in that regard. Therefore, a double blind placebo controlled study is conducted, to examine the effects of spironolactone on cardiac and skeletal muscle-function in chronic alcoholics.

Conditions

  • Cardiomyopathy, Alcoholic
  • Alcoholism

Interventions

DRUG

spironolactone

100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Hendrik Vilstrup, Proffessor · Univeristy of Aarhus

  • Peter Holland-Fischer, MD · University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2011-08-31
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226109 on ClinicalTrials.gov